MEMBRANE PEPTIDE STRUCTURE VIA NMR & QUANTUM CHEMISTRY

通过 NMR 观察膜肽结构

基本信息

  • 批准号:
    6281472
  • 负责人:
  • 金额:
    $ 2.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-01-15 至 1999-01-14
  • 项目状态:
    已结题

项目摘要

The SIR provided L-[2- 13 C]Tryptophan; 2g L-13- 13C]Tryptophan; 1.25g The idea behind this project is to make 13C-labeled gramicidins, as prototypical membrane penetrating peptide/protein fragments, and to explore their structure using the ISOTROPIC CARBON- 13 CHEMICAL SHIF'F, plus quantum chemistry, as a probe of structure. Previous work has always focused on orientational (15N, 2H, some 13C) information - the position of a line in an oriented sample, rather than completely analyzing chemical shifts using quantum chemistry, which is what we propose here. The ability to analyze isotropic chemical shifts in proteins in structural terms has a good chance of making may more systems amenable to investigation, and Ca, Cb, Cg of Trp in gramicidin should be excellent probes (especially since the Trps are functionally significant). By combining the observed isotropic chemical shifts with the quantum chemically computed shielding surfaces, one obtains for Trp the solutions for c 1, c2 as well as f, y, c 1 results for Val, Leu. These unique solutions remove problems associated with may dipolar or quadrupolar derived geometry restraints, ans when combined with the often more accurate (but multivalued) tensor data should yield very accurate, unique NMR solutions, for f, y, c I, c2. Knowledge of Trp orientations is important for understanding gramicidin action, and the above results (together) with those we are planning to obtain with commercially available 13C glycines and alanines) should together clearly indicate the utility of chemical shifts in structure studies, especially since the chemical shift is, in a sense, the most fundamental NMR property.
SIR提供L-[2- 13 C]色氨酸;2 g

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eric Oldfield其他文献

Eric Oldfield的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eric Oldfield', 18)}}的其他基金

Next generation bisphosphonates for chemo- and immuno-therapy
用于化疗和免疫治疗的下一代双膦酸盐
  • 批准号:
    8444316
  • 财政年份:
    2011
  • 资助金额:
    $ 2.13万
  • 项目类别:
Next generation bisphosphonates for chemo- and immuno-therapy
用于化疗和免疫治疗的下一代双膦酸盐
  • 批准号:
    8627146
  • 财政年份:
    2011
  • 资助金额:
    $ 2.13万
  • 项目类别:
Next generation bisphosphonates for chemo- and immuno-therapy
用于化疗和免疫治疗的下一代双膦酸盐
  • 批准号:
    8825340
  • 财政年份:
    2011
  • 资助金额:
    $ 2.13万
  • 项目类别:
Next generation bisphosphonates for chemo- and immuno-therapy
用于化疗和免疫治疗的下一代双膦酸盐
  • 批准号:
    8085202
  • 财政年份:
    2011
  • 资助金额:
    $ 2.13万
  • 项目类别:
COMPLEX OF FPPS-PV
FPPS-PV复合体
  • 批准号:
    8170665
  • 财政年份:
    2010
  • 资助金额:
    $ 2.13万
  • 项目类别:
Prenyl Diphosphate Synthase Inhibitors
异戊二烯二磷酸合酶抑制剂
  • 批准号:
    6846172
  • 财政年份:
    2002
  • 资助金额:
    $ 2.13万
  • 项目类别:
Prenyl Synthase Inhibitors: Novel Anti-Infective Agents
异戊二烯合酶抑制剂:新型抗感染剂
  • 批准号:
    7984564
  • 财政年份:
    2002
  • 资助金额:
    $ 2.13万
  • 项目类别:
Prenyldiphosphate Synthase Inhibitors: Novel Anti-Infective Agents
异戊二烯二磷酸合酶抑制剂:新型抗感染剂
  • 批准号:
    7686803
  • 财政年份:
    2002
  • 资助金额:
    $ 2.13万
  • 项目类别:
Prenyl Diphosphate Synthase Inhibitors
异戊二烯二磷酸合酶抑制剂
  • 批准号:
    6622937
  • 财政年份:
    2002
  • 资助金额:
    $ 2.13万
  • 项目类别:
Prenyl Synthase Inhibitors: Novel Anti-Infective Agents
异戊二烯合酶抑制剂:新型抗感染剂
  • 批准号:
    8532682
  • 财政年份:
    2002
  • 资助金额:
    $ 2.13万
  • 项目类别:

相似海外基金

Molecular Imaging Biomedical Resource Core
分子成像生物医学资源核心
  • 批准号:
    10747619
  • 财政年份:
    2023
  • 资助金额:
    $ 2.13万
  • 项目类别:
Biomedical Resource Core
生物医学资源核心
  • 批准号:
    10747705
  • 财政年份:
    2023
  • 资助金额:
    $ 2.13万
  • 项目类别:
Intravital Microscopy Biomedical Resource Core
活体显微镜生物医学资源核心
  • 批准号:
    10747618
  • 财政年份:
    2023
  • 资助金额:
    $ 2.13万
  • 项目类别:
Biomedical Resource Core
生物医学资源核心
  • 批准号:
    10754083
  • 财政年份:
    2023
  • 资助金额:
    $ 2.13万
  • 项目类别:
National Biomedical Resource for Electron-Spin Resonance Spectroscopy (ACERT)
国家电子自旋共振光谱生物医学资源 (ACERT)
  • 批准号:
    10797623
  • 财政年份:
    2022
  • 资助金额:
    $ 2.13万
  • 项目类别:
National Biomedical Resource for Electron-Spin Resonance Spectroscopy (ACERT)
国家电子自旋共振光谱生物医学资源 (ACERT)
  • 批准号:
    10653773
  • 财政年份:
    2022
  • 资助金额:
    $ 2.13万
  • 项目类别:
National Biomedical Resource for Electron-Spin Resonance Spectroscopy (ACERT)
国家电子自旋共振光谱生物医学资源 (ACERT)
  • 批准号:
    10430665
  • 财政年份:
    2022
  • 资助金额:
    $ 2.13万
  • 项目类别:
The 1958 Birth Cohort Biomedical Resource - facilitating access to data and samples and enhancing future utility
1958 年出生队列生物医学资源 - 促进数据和样本的获取并增强未来的效用
  • 批准号:
    G1001799/2
  • 财政年份:
    2013
  • 资助金额:
    $ 2.13万
  • 项目类别:
    Research Grant
The 1958 Birth Cohort Biomedical Resource - facilitating access to data and samples and enhancing future utility
1958 年出生队列生物医学资源 - 促进数据和样本的获取并增强未来的效用
  • 批准号:
    G1001799/1
  • 财政年份:
    2011
  • 资助金额:
    $ 2.13万
  • 项目类别:
    Research Grant
Vervet Research Colony as a Biomedical Resource
作为生物医学资源的黑长尾黑长尾猴研究群
  • 批准号:
    7894014
  • 财政年份:
    2009
  • 资助金额:
    $ 2.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了